Reprint

Pheochromocytoma (PHEO) and Paraganglioma (PGL)

Edited by
November 2019
380 pages
  • ISBN978-3-03921-654-3 (Paperback)
  • ISBN978-3-03921-655-0 (PDF)

This is a Reprint of the Special Issue Pheochromocytoma (PHEO) and Paraganglioma (PGL) that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

This book outlines some new advances in genetics, clinical evaluation, localization, therapy (newly including immunotherapy) of pheochromocytoma and paraganglioma including their metastatic counterparts. Well-known and experienced clinicians and scientists contributed to this book to include some novel approaches to these tumors. This book will serve to various health care professionals from different subspecialties, but mainly oncologists, endocrinologists, endocrine surgeons, pediatricians, and radiologists. This book shows that the field of pheochromocytoma/paraganglioma is evolving and a significant progress has been made in last 5 years requiring that health care professionals and scientists will learns new information and implement it in their clinical practice or scientific work, respectively. This book should not be missed by anybody who is focusing on neuroendocrine tumors, their newest evaluation and treatment.

Format
  • Paperback
License and Copyright
© 2020 by the authors; CC BY license
Keywords
pheochromocytoma; paraganglioma; adrenocortical carcinoma; adrenal tumor; pan-cancer analysis; neural crest; neuroendocrine; paraganglioma; head and neck; radiotherapy; 18F-FDOPA; PET; GTV; SDHB; SDHD; mortality; paraganglioma; pheochromocytoma; radiofrequency ablation; cryoablation; percutaneous ethanol injection; neuroendocrine tumor; minimally invasive procedure; percutaneous ablation; PASS; GAPP; histology; meta-analysis; paraganglioma; pheochromocytoma; carotid body; angiogenesis; mitochondria; neural crest; neurogenesis; paraganglioma; stem-like tumor cells; vasculogenesis; xenograft; pheochromocytoma; catecholamine; global longitudinal strain; speckle-tracking echocardiography; subclinical systolic dysfunction; pheochromocytoma; paraganglioma; neuroendocrine tumor; targeted therapy; therapy resistance; FGF21; pheochromocytoma; paraganglioma; diabetes mellitus; obesity; energy metabolism; calorimetry; chromogranin A; metanephrines; pheochromocytoma; paraganglioma; hypoxia; pseudohypoxia; spheroids; HIF; EPAS1; catecholamine; pheochromocytoma and paraganglioma; phosphorylation tyrosine hydroxylase; dog; pheochromocytoma; paraganglioma; SDHB; SDHD; mutation; chromosomal alteration; comparative genomics; pheochromocytoma; paraganglioma; metastatic; immunotherapy; innate immunity; adaptive immunity; toll-like receptor; pathogen-associated molecular patterns; neutrophil; T cell; pheochromocytoma; paraganglioma; hypertension; blood pressure variability; average real variability; weighted standard deviation; paraganglioma; somatostatinoma; polycythemia; EPAS1; transgenic mice; erythropoietin; pheochromocytoma; paraganglioma; TCA cycle; germline mutation; metastatic OR malignant pheochromocytoma; paraganglioma; ectopic secretion; lL-6; normetanephrines; VHL; NF1; EPAS1; hypoxia-inducible factor; inflammation; radiosensitization; succinate dehydrogenase; mouse pheochromocytoma cells; immunohistochemistry; fluorescence imaging; pheochromocytoma; paraganglioma; next-generation sequencing; sporadic; hereditary; CNV detection; pheochromocytoma; paraganglioma; PET-CT; 11C-hydroxy-ephedrine; adrenal incidentaloma; pheochromocytoma; paraganglioma; 177Lu-DOTATATE; peptide receptor radiotherapy; PRRT; neuroendocrine tumor; NET; PCC; PGL; postoperative; pheochromocytoma; hypertension; hypotension; arrhythmia; PPGL; catecholamines; adrenomedullary function; n/a